Doug is co-Founder, President & CEO of Dicerna Pharmaceuticals, a second generation RNA interference company developing therapeutics for rare diseases and other liver diseases. Prior to taking the CEO role at Dicerna, Doug was a General Partner with the venture capital firm Oxford Bioscience Partners. During his 10+ years at Oxford, Doug specialized in financing innovative life science technology companies, such as first generation RNA Interference pioneer Sirna Therapeutics, acquired by Merck for $1.1 billion; Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million, and now responsible for a large majority of the DNA sequencing done today. Before joining Oxford, Doug was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). He graduated from Cornell University and obtained his Ph.D. in Genetics at the University of California, Berkeley.